Literature DB >> 14994334

Calcium channel blockers in the treatment of disease.

Keith S Elmslie1.   

Abstract

Over the last 20 years the combination of patch clamp and molecular biology techniques have resulted in an explosion in our knowledge of the different calcium channel types and their roles in physiology. A crucial component to this advance has been the discovery of specific blockers for different calcium channel types. These blockers have not only permitted researchers to assign specific functions to different channel types, but their specificity allowed them to be used to treat diseases that resulted from enhanced calcium channel function. In some cases, the enhanced calcium channel function is secondary to other problems leading to increased cellular excitability. The specificity of calcium channel blockers, however, has provided a means to treat symptoms of the pathophysiology until more effective treatments become available to address the underlying problems. The goal of this review is to introduce the various types of calcium channels, their primary physiologic roles, drugs that block these channels, and diseases that are currently being treated with these drugs. Copyright 2004 Wiley-Liss, Inc.

Mesh:

Substances:

Year:  2004        PMID: 14994334     DOI: 10.1002/jnr.10872

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  18 in total

1.  A chemical genetics approach reveals H,K-ATPase-mediated membrane voltage is required for planarian head regeneration.

Authors:  Wendy S Beane; Junji Morokuma; Dany S Adams; Michael Levin
Journal:  Chem Biol       Date:  2011-01-28

2.  Painful peripheral nerve injury decreases calcium current in axotomized sensory neurons.

Authors:  J Bruce McCallum; Wai-Meng Kwok; Damir Sapunar; Andreas Fuchs; Quinn H Hogan
Journal:  Anesthesiology       Date:  2006-07       Impact factor: 7.892

Review 3.  A short history of voltage-gated calcium channels.

Authors:  Annette C Dolphin
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  TLR4-initiated and cAMP-mediated abrogation of bacterial invasion of the bladder.

Authors:  Jeongmin Song; Brian L Bishop; Guojie Li; Matthew J Duncan; Soman N Abraham
Journal:  Cell Host Microbe       Date:  2007-06-14       Impact factor: 21.023

5.  Identification of CaV channel types expressed in muscle afferent neurons.

Authors:  Renuka Ramachandra; Bassil Hassan; Stephanie G McGrew; James Dompor; Mohamed Farrag; Victor Ruiz-Velasco; Keith S Elmslie
Journal:  J Neurophysiol       Date:  2013-07-10       Impact factor: 2.714

6.  Domain III regulates N-type (CaV2.2) calcium channel closing kinetics.

Authors:  Viktor Yarotskyy; Guofeng Gao; Blaise Z Peterson; Keith S Elmslie
Journal:  J Neurophysiol       Date:  2011-12-28       Impact factor: 2.714

7.  Phospholemman modulates the gating of cardiac L-type calcium channels.

Authors:  Xianming Wang; Guofeng Gao; Kai Guo; Viktor Yarotskyy; Congxin Huang; Keith S Elmslie; Blaise Z Peterson
Journal:  Biophys J       Date:  2010-04-07       Impact factor: 4.033

8.  Roscovitine inhibits CaV3.1 (T-type) channels by preferentially affecting closed-state inactivation.

Authors:  Viktor Yarotskyy; Keith S Elmslie
Journal:  J Pharmacol Exp Ther       Date:  2011-11-16       Impact factor: 4.030

9.  The Timothy syndrome mutation of cardiac CaV1.2 (L-type) channels: multiple altered gating mechanisms and pharmacological restoration of inactivation.

Authors:  Viktor Yarotskyy; Guofeng Gao; Blaise Z Peterson; Keith S Elmslie
Journal:  J Physiol       Date:  2008-12-15       Impact factor: 5.182

10.  Roscovitine binds to novel L-channel (CaV1.2) sites that separately affect activation and inactivation.

Authors:  Viktor Yarotskyy; Guofeng Gao; Lei Du; Sindura B Ganapathi; Blaise Z Peterson; Keith S Elmslie
Journal:  J Biol Chem       Date:  2009-11-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.